NASDAQ:ENGN

enGene Q3 2025 Earnings Results & Report

enGene logo
$1.74 -0.03 (-1.42%)
As of 12:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

enGene missed analyst earnings expectations in its Q3 2025 results, released September 11, 2025. The company reported EPS of -$0.57 versus the -$0.5084 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
9:30 AM ET

enGene EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.5084
Beat/Miss
Missed by -$0.0616
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

enGene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

enGene's Q4 2026 earnings is estimated for Tuesday, December 22, 2026, based on past reporting schedules, with a conference call scheduled on Friday, December 18, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

enGene Q3 2025 Earnings FAQ

enGene (NASDAQ:ENGN) reported earnings of -$0.57 per share for Q3 2025, missing the consensus estimate of -$0.5084. The report was announced on Thursday, September 11, 2025.

enGene's next earnings date is estimated for Tuesday, December 22, 2026. MarketBeat tracks confirmed and estimated earnings dates for enGene on the company's earnings history page.

enGene Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
enGene (NASDAQ:ENGN) Upgraded at Leerink Partners
See More enGene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email.

About enGene

enGene (NASDAQ:ENGN) is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

View enGene Profile